Get the Daily Brief
Latest Biotech News
New AI Models Capture Complex Gene Networks in Cells
Researchers from Columbia University and the Chan Zuckerberg Initiative have developed GREmLN, a graph-based artificial intelligence model designed to capture complex long-range gene regulatory...
Liquid Biopsy Using Microbial RNA Modifications Predicts Colorectal Cancer
Researchers at the University of Chicago introduced a novel liquid biopsy test employing modification patterns in microbiome-derived cell-free RNA to detect colorectal cancer (CRC) with superior...
Merck Boosts Respiratory Portfolio with $10 Billion Verona Buyout
Merck & Co. has agreed to acquire London-based Verona Pharma for $10 billion, integrating Verona's Ohtuvayre, a first-in-class dual inhibitor of phosphodiesterase 3 and 4 approved for chronic...
AbbVie Invests $700 Million in Trispecific Antibody for Multiple Myeloma
AbbVie announced a $700 million upfront payment to IGI Therapeutics for rights to ISB 2001, a trispecific antibody designed to bind three targets involved in multiple myeloma treatment. The...
FDA Publishes Drug Rejection Letters in Historic Transparency Shift
The U.S. Food and Drug Administration publicly released an initial batch of over 200 complete response letters (CRLs) issued from 2020 to 2024, marking the first time such drug rejection documents...
AI-Driven Collaboration Targets Oncology Drug Discovery
Revolution Medicines and Iambic Therapeutics have formed a multi-year alliance leveraging Iambic’s AI-based drug discovery platforms. The collaboration focuses on applying NeuralPLexer, a...
Soleno Therapeutics’ Rare Disease Drug Sales Outpace Expectations
Soleno Therapeutics reported initial quarterly revenue from its rare disease drug Vykat XR between $31 million and $33 million for the quarter ending June 30, surpassing Wall Street expectations....
Geneoscopy’s Patent Victory Against Exact Sciences in Colorectal Cancer Test
The U.S. Patent Trial and Appeal Board invalidated Exact Sciences’ patent covering a key component of its Cologuard colorectal cancer screening assay following a challenge by Geneoscopy. The PTAB...
Chan Zuckerberg Initiative and Columbia Develop AI Virtual Human Cell Model
Researchers at Columbia University and the Chan Zuckerberg Initiative (CZI) introduced GREmLN, an AI-based virtual human cell model designed to predict cellular state transitions in health and...
Radiopharmaceutical Biotechs Nuclidium and Actithera Secure Major Funding
Two European radiopharmaceutical companies are advancing their clinical and development programs with significant funding rounds. Nuclidium AG raised $99 million in Series B financing to progress...
Advancements in Cancer Liquid Biopsy using Microbiome-Derived RNA Modifications
University of Chicago scientists have developed a novel liquid biopsy test that utilizes low-input multiple methylation sequencing (LIME-seq) to detect RNA modifications in plasma cell-free RNA...
Merck Makes $10 Billion Bet on COPD With Verona Pharma Acquisition
Merck & Co. has agreed to acquire London-based Verona Pharma for $10 billion, centered on the recently approved COPD drug Ohtuvayre. The FDA approved Ohtuvayre in June 2024 as the first inhaled...
FDA Publishes Drug Rejection Letters in Historic Transparency Move
The U.S. Food and Drug Administration has taken a historic step by releasing an initial batch of more than 200 drug rejection letters, referred to as complete response letters (CRLs). These...
Actithera Raises $75.5 Million Series A to Advance Radiopharmaceutical Cancer Drug
Radiopharmaceutical startup Actithera has secured $75.5 million in Series A funding to propel clinical development of a novel treatment targeting fibroblast activation protein (FAP) expressed in...
Personalis and Tempus Expand Partnership for Cancer MRD Detection
Personalis has extended its strategic collaboration with Tempus AI to broaden commercialization of the NeXT Personal minimal residual disease (MRD) assay into colorectal cancer, adding to prior...
Revolution Medicines, Iambic Team Up for AI-Driven Cancer Drug Discovery
Oncology-focused Revolution Medicines has initiated a multi-year collaboration with AI drug discovery firm Iambic Therapeutics worth up to $25 million. Iambic will train its NeuralPLexer...
Chan Zuckerberg Initiative and Columbia Researchers Develop AI Virtual Cell Model GREmLN
A novel AI model named GREmLN (Gene Regulatory Embedding-based Large Neural model) has been developed by Columbia University and Chan Zuckerberg Initiative researchers to improve predictions of...
AbbVie Acquires Ichnos Glenmark’s Trispecific Antibody for Multiple Myeloma
AbbVie has agreed to pay $700 million upfront to acquire rights to ISB 2001, a trispecific antibody developed by Ichnos Glenmark Therapeutics targeting multiple myeloma. The antibody engages CD3...
Aqtual Secures $31 Million Series B to Advance Rheumatoid Arthritis Therapy Selection Assay
Precision medicine startup Aqtual has raised $31 million in an oversubscribed Series B financing to support commercialization of its cell-free DNA-based assay predicting patient response to...
Soleno Therapeutics’ Rare Disease Drug Vykat XR Sales Outpace Expectations
Soleno Therapeutics reported second-quarter sales of Vykat XR, its rare disease drug approved for Prader-Willi syndrome, significantly exceeding analyst forecasts with $31-33 million in revenue....